2026-08-18
Media-led ingest + verification — age-related cataract and lanosterol
Applied scraping-youtube-references to YouTube video A6rLV7qPcXQ, Is This the End of Cataract Surgery? New US Trial Begins, as a discovery lead only. The description supplied no scientific reference list, so each material transcript claim was resolved independently to a primary paper, trial registration, patent, or authoritative clinical source; neither the video nor its presenter is cited as biological evidence.
Seeded age-related-cataract, lens, lanosterol, and zoc2017217, plus atomic study pages for the original positive lanosterol report, negative human-nucleus and rat/human-lens replications, the positive isolated-human-aggregate assay, human genetics, the cynomolgus-monkey depot study, rat LSS-mRNA delivery, and the post-hoc EDTA subgroup. The compound and phenotype pages separate parent lanosterol, the chemically undisclosed ZOC2017217 development code, and injected transient LSS mRNA rather than treating them as one intervention.
The evidence picture is mixed and model-dependent. Zhao 2015 reported positive biochemical, rabbit-lens, and canine signals; Shanmugam 2015 found no agreed clearing in excised human cataract nuclei; Chen 2018 reported dissociation only after aggregates were isolated from human surgical material; Daszynski 2019 found no reversal in induced rat lenses and no protein-solubility signal in aged human lens material; Zhang 2022 reported a transient cortical-cataract signal in three monkeys but little nuclear response; and no controlled living-human efficacy result for parent lanosterol was found. A 2025 rat study used intracameral lipid-nanoparticle LSS mRNA and is not genome editing or an eye-drop trial.
The current NCT07395986 structured record was checked directly: ACTIVE_NOT_RECRUITING, 8 actual participants, 0.4% ZOC2017217 versus placebo, and estimated primary/study completion in February 2027. Its retained narrative still says approximately 40 participants, so the wiki records the inconsistency instead of silently combining the fields. Six Chinese registrations are listed as mirror-corroborated because official detail pages were access-gated; no public result table or peer-reviewed ZOC2017217 efficacy paper was located. The related patent family does not map the code to an exact structure, so canonical chemical identifiers, targets, and mechanisms remain null/empty.
The verifier pass corrected a nonexistent 2026 single-cell citation to the real 2025 Research Square preprint, narrowed the EDTA result to a post-hoc 41-eye subgroup, separated prevention from reversal in the LSS-mRNA rat models, and preserved cataract-subtype and delivery-route boundaries. Castor-oil trials located in the literature concern blepharitis, meibomian-gland dysfunction, and tear-film endpoints—not crystalline-lens opacity—and were not promoted as cataract evidence.
Propagation added the lens and cataract to the nervous-system overlay and linked the new phenotype from UV protection. No public page links to the private protocol tree.